Synthetic Oligonucleotide Analysis

A resurgence in oligonucleotide therapeutic development has led to a rapidly expanding preclinical/clinical pipeline. Working at the level of gene transcription and translation, these short-chain nucleic acid drugs hold great promise for many inherited disorders and common ailments alike.

For more than a decade, Waters has been leading the development of advanced tools and techniques for synthetic oligonucleotide characterization, purification and bioanalysis. With passion, dedication and focus, we remain committed to helping our customers solve their most difficult analytical challenges. From our innovative high-performance chromatography columns and sample prep consumables, to our suite of LC, MS and Light Scattering instruments, to our compliance-ready software and application-based workflows, to our unrivaled service and support, we stand ready to help you succeed with your synthetic oligonucleotide development goals.

Pipelines expand, molecules complexify. Your analytics must keep pace.

Accelerate pipeline success: Navigate the expanding preclinical and clinical landscape for short-chain nucleic acid drugs with ease.

Ensure product integrity: Confirm absolute identity and purity of therapeutic candidates using leading-edge LC-MS tools.

Optimize bioanalysis: Streamline DMPK studies with precise extraction and quantification from complex biological samples.

With oligonucleotide therapeutics, the sequence and location of modified nucleotides are of critical importance to their function, stability, and efficacy. LC-MS/MS fragmentation is a key technique that can provide this level of sequence confirmation, and automated data analysis and reporting tools make the process fast and easy.